LSD1 inhibition has now been well validated as a therapeutic approach in essential thrombocythemia (ET) and other MPNs, with multiple agents demonstrating consistent effects on hematologic parameters and emerging signals of disease modification.

However, as more fully described Science Advances, targeting LSD1 alone may be insufficient to fully disrupt CoREST‑driven biology, as the system depends on multi-component and non‑catalytic interactions. JBI‑802 was designed with this in mind, combining LSD1 inhibition with HDAC6 to extend beyond the CoREST complex and target complementary regulatory pathways such as JAK‑STAT signaling, enabling a more complete and potentially durable biological response.